Brexpiprazole is a serotonin-dopamine activity modulator structurally related to aripiprazole, offering partial D2/5-HT1A agonism and 5-HT2A antagonism with a refined receptor-binding profile, used for schizophrenia and as adjunct therapy in major depressive disorder. Simson Pharma's Brexpiprazole reference standard and impurities support stability-indicating method development for this newer-generation antipsychotic.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Brexpiprazole Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.